Cencora, Inc. $COR Shares Sold by Diversified Trust Co

Diversified Trust Co trimmed its holdings in Cencora, Inc. (NYSE:COR) by 11.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,222 shares of the company’s stock after selling 5,942 shares during the quarter. Diversified Trust Co’s holdings in Cencora were worth $13,560,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Grove Bank & Trust increased its stake in Cencora by 4.3% during the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after acquiring an additional 36 shares during the last quarter. Clare Market Investments LLC increased its position in shares of Cencora by 34.7% during the second quarter. Clare Market Investments LLC now owns 11,790 shares of the company’s stock valued at $3,535,000 after acquiring an additional 3,040 shares during the last quarter. Redhawk Wealth Advisors Inc. raised its stake in shares of Cencora by 6.5% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 12,507 shares of the company’s stock valued at $3,750,000 after acquiring an additional 760 shares during the period. Contravisory Investment Management Inc. lifted its holdings in shares of Cencora by 0.7% in the 2nd quarter. Contravisory Investment Management Inc. now owns 5,382 shares of the company’s stock worth $1,614,000 after acquiring an additional 40 shares during the last quarter. Finally, Ferguson Wellman Capital Management Inc. boosted its position in shares of Cencora by 61.5% during the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 208,516 shares of the company’s stock worth $62,524,000 after purchasing an additional 79,430 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Down 0.2%

COR stock opened at $290.32 on Friday. The company has a 50 day moving average price of $292.42 and a two-hundred day moving average price of $286.81. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock has a market capitalization of $56.29 billion, a P/E ratio of 29.87, a PEG ratio of 1.38 and a beta of 0.62. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter in the previous year, the business earned $3.34 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the transaction, the chief executive officer directly owned 42,351 shares in the company, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 65,475 shares of company stock worth $19,080,900 in the last quarter. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Jefferies Financial Group boosted their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Finally, Morgan Stanley set a $330.00 price objective on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $311.25.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.